IDEXX Laboratories, Inc. vs Skyworks Solutions Inc — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Skyworks Solutions Inc trades at $76.35 (market cap $12.15B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3.3× Skyworks Solutions Inc's market cap, and Skyworks Solutions Inc pays a 4.13% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Skyworks Solutions Inc for 50 Days on average.
| IDXX | SWKS | |
|---|---|---|
Market Cap | $40.43B | $12.15B |
Volume | 692,164 | 7,390,810 |
Sector | Health | Technology |
52-Week High | $766.68 | $91.45 |
52-Week Low | $504.70 | $52.50 |
Typical Hold Time | 46 Days | 50 Days |
Enterprise Value | $41.32B | $12.03B |
Dividend Yield | — | 4.13% |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
Skyworks Solutions (SWKS) trades at $80.75, down 3.21% today, with a bearish technical signal despite recent earnings beats. The company shows declining revenue and profit margins over recent years, with 2025 revenue at $4.09B and net income of $477.1M. Key developments include the pending Qorvo merger, which has driven recent volatility and analyst optimism about potential synergies.
The investment outlook is mixed: strong analyst support (60% buy ratings) and merger potential offer upside, but declining fundamentals and bearish technicals present near-term risks. The consensus price target of $78.80 suggests limited upside from current levels, making careful monitoring of merger progress and Q3 earnings crucial.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →